Transgene Biotek Ltd.

Here is the company profile for Transgene Biotek Ltd. (TRABI) for the financial year ended March 31, 2025, based on the attached Annual Report:

Business overview Transgene Biotek Ltd. (TRABI) is primarily engaged in research and development (R&D) activities, generating revenue from R&D services provided to external agencies. A significant focus for the company is on alternative drug delivery technologies, particularly the oral delivery of insulin. The company's operations are largely based in India, with a subsidiary previously active in Hong Kong.

Key facts

• FY2024-25 Total Income: Rs. 104.42 Lakhs (Standalone and Consolidated).
• FY2024-25 Net Loss: Rs. 67.61 Lakhs (Standalone and Consolidated).
• Promoter Shareholding (as of March 31, 2025): 21.68%.
• Outstanding Global Depository Receipts (GDRs): 62,70,000, representing 8.28% of total shares.
• Wholly-owned subsidiary Transgene Biotek HK Ltd's operations have been suspended since FY2015-16 and its accounts have not been audited since then.
• Dr. K. Koteswara Rao, the Chairman & Managing Director, aged 83, holds 22% of the company's shares.

Recent developments (from concall / AR)

• Management is exploring a strategic alternative given regulatory limitations and SEBI-imposed restrictions until legal orders are vacated.
• A technology transfer of "NiedlFree Technologies" (oral insulin drug delivery) to NiedlFree Technologies has been initiated with the hope of recouping company value.
• NiedlFree management reported encouraging preliminary clinical study results for Oral Insulin and is pursuing necessary regulatory approvals for the next steps.
• The company repaid the full principal amount of Rs. 3.87 Crores to BIRAC in February 2025, awaiting confirmation of full and final settlement for the total outstanding amount of Rs. 7.58 Crores (including penal interest).
• Succession planning for the Managing Director, Dr. K. Koteswara Rao, has been initiated due to his deteriorating health and advanced age, with his retirement anticipated in FY 2025-26.

Key risks flagged by management

• The company faces multiple legal and financial challenges, including ongoing cases at the Securities Appellate Tribunal (SAT), Appellate Tribunal (ED), and National Company Law Tribunal (NCLT).
• Operations are "paralyzed" due to penalties and restrictions imposed by SEBI, hindering the company's ability to sustain its activities.
• Uncertainty exists regarding the recovery of approximately USD 39.9 million in GDR funds, which management alleges were fraudulently siphoned.
• A substantial monetary penalty of Rs. 203.02 Crores was imposed by the Enforcement Directorate for alleged contraventions under the Foreign Exchange Management Act (FEMA).

Pros

• The company maintains R&D focus on alternative drug delivery, with promising preliminary clinical results for its Oral Insulin project through NiedlFree.
• Management is actively pursuing legal avenues to recover significant siphoned GDR funds and challenge adverse regulatory orders.
• The company states a commitment to good corporate governance practices and conducts regular board performance evaluations.

Cons

• Transgene Biotek reported a net loss of Rs. 67.61 Lakhs for FY2024-25, and directors were unable to recommend a dividend due to unprofitability.
• Auditors expressed a material uncertainty regarding the company's ability to continue as a "going concern" and could not confirm the recoverability of significant investments and GDR advances.
• Significant compliance issues persist, including several independent directors whose terms expired without re-appointment, frozen bank and demat accounts by SEBI due to an unpaid penalty, and outstanding statutory dues. The impending retirement of the aging Managing Director also poses a leadership transition challenge.